ClinicalTrials.gg
CompletedNCT00544713Updated Dec 14, 2011Results posted

Evaluate the Safety and Efficacy of a New Artificial Tear for Use After LASIK Surgery

An interventional study of Carboxymethylcellulose and Glycerin based artificial tear and Carboxymethylcellulose in Dry Eye Syndrome, sponsored by Allergan. Completed at 1 site in United States. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2011-12-14.

Sponsored by Allergan (part of AbbVie) · Not applicable, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
228
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 48 studies in Dry Eye Syndromes by AbbVie — 1 open to participants now, 1 under way, none of them phase 3. Dry Eye Syndromes · AbbVie.

Enrollment
13th of 40
228 · median 80
Started
2007
with 3 others
No phase
11 of 48
none open now
Registered
4th of 48
by date

Among the 48 studies in Dry Eye Syndromes by AbbVie, this one is the 13th largest by enrollment of the 40 interventional ones that give a count, is one of 4 that started in 2007, is one of 11 with no phase, and was the 4th registered.

Dry Eye Syndromes

1,369 studies on the registry are indexed under Dry Eye Syndromes; 208 are open to participants now.

Browse Dry Eye Syndromes studies →

Open to participants now

1 of the 48 studies in Dry Eye Syndromes by AbbVie is open now, in 3 countries. Recruiting first, the newest first:

By country, each count listing its studies:

Who these studies take

Of the 116 Dry Eye Syndromes studies recruiting now, 73 (63%) set no upper age limit and 24 (21%) stop at 75 or younger; 7 take children under 18; 29 take healthy volunteers.

This study: 18 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 48 studies in Dry Eye Syndromes by AbbVie, or all of them as a file.
02

Study summary

This study will evaluate the safety and efficacy of a new artificial tear for the treatment of dry eye that may occur after LASIK surgery

03

Conditions studied

  • Dry Eye Syndrome

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Candidate for bilateral LASIK surgery for myopia correction in the range of -1.00 to -8.00 diopters

Exclusion criteria

Exclusion Criteria:

  • Dry eye signs and symptoms
  • Preoperative soft or rigid contact lens wear within last 7 or 30 days, respectively
  • Pregnancy or planning pregnancy
  • Uncontrolled systemic disease
  • Use of systemic medications affecting dry eye
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
228 participants (actual)

Study arms

  • Experimental
    Carboxymethylcellulose and Glycerin based artificial tear

    Carboxymethylcellulose and Glycerin based artificial tear

    Drug: Carboxymethylcellulose and Glycerin based artificial tear

  • Active comparator
    Carboxymethylcellulose based artificial tear

    Carboxymethylcellulose based artificial tear

    Drug: Carboxymethylcellulose

Interventions

  • DrugCarboxymethylcellulose and Glycerin based artificial tear

    As directed by Investigator at the end of each study visit: 1 to 2 drops in each eye, 1 to 2 times a day up to every hour while awake

  • As directed by Investigator at the end of each study visit: 1 to 2 drops in each eye, 1 to 2 times a day up to every hour while awake

    Also known as: Refresh Plus®

06

What researchers measure

Primary outcomes

  1. Post LASIK Dry Eye Symptoms as Measured by Ocular Surface Disease Index (OSDI©) Score at Day 90

    Measured on 12 domains (categories); a 5-point scale for each domain (0 = best, no dry eye symptoms, 4 = worst, constant dry eye symptoms). Sum of the domain scores is normalized (standardized) to a severity scale of 0-100 (0 = no symptoms (best score), 100 = maximum severity (worst score)).

    Time frame: Day 90

Secondary outcomes

  1. Patient Acceptability- Percentage of Patients Who Rated Artificial Tears (AT) as Acceptable at Day 90

    A questionnaire was administered to all patients to evaluate the acceptability of the Artificial Tears (referred to as AT). Percentage of patients responding either "Agree" or "Strongly Agree" at day 90 was tabulated. The potential response categories included "Strongly Agree", "Agree", "Neither Agree Nor Disagree", "Disagree" and "Strongly Disagree".

    Time frame: Day 90

  2. Patient Acceptability (Sensory) - Percentage of Patients Who Rated Artificial Tears (AT) as Acceptable at Day 90

    A patient acceptability - sensory questionnaire was administered to all patients to evaluate the acceptability of the Artificial Tears (AT). Percentage of patients responding either "Agree" or "Strongly Agree" at day 90 was tabulated. The potential response categories included "Strongly Agree", "Agree", "Neither Agree Nor Disagree", "Disagree" and "Strongly Disagree".

    Time frame: Day 90

  3. Best Corrected Visual Acuity (BCVA) Status at Day 90

    BCVA status at Day 90 reported as the number of patients whose scores were either "Better", "No Change", or "Worse" than their scores at baseline. The status was tabulated as number of lines read correctly at Day 90 minus the number of lines read correctly at baseline. "Better" equals increase of 2 lines or more; "No Change" equals change between -2 to +2 lines; "Worse" equals decrease of 2 lines or more. BCVA is measured using a special eye chart a nd is reported as the number of lines (5 letters per line) read correctly.

    Time frame: Day 90

  4. Change From Baseline of the Worse Eye in Corneal Topography as Measured by Pentacam at Day 90

    Change from Baseline in corneal topography of the worse eye as measured using a Pentacam system which calculates a number. Corneal topography is a non-invasive medical imaging technique for mapping the surface of the eye. The Pentacam system measures the pupil and anterior segment (the front part of the eye) which provides a range from 10 (best) to 60 (worst). A negative number change from baseline indicates an improvement.

    Time frame: Baseline, Day 90

  5. Change From Baseline of the Worse Eye in Corneal Topography Measured by Humphrey Atlas at Day 90

    Change from Baseline in corneal topography of the worse eye as measured by a Humphrey Atlas system which calculates a number. Corneal topography is anon-invasive medical imaging technique for mapping the surface curvature of the cornea (the outer structure of the eye). The higher the number the more irregular the cornea. A Humphrey Atlas system detects irregular conditions in the cornea with a range from 0 = best to 2.5 = worst. A negative number change from baseline indicates an improvement.

    Time frame: Baseline, Day 90

  6. Change From Baseline of Total Higher Order Aberration (HOA) of the Worse Eye at Day 90

    Change from Baseline in total HOA of the worse eye. The total HOA number is measured using a machine that calculates and detects changes in the cornea which could occur post Lasik surgery. A negative number change from baseline indicates an improvement.

    Time frame: Baseline, Day 90

  7. Change From Baseline of the Worse Eye in Schirmer's Test at Day 90

    Change from baseline in Schirmer's Test results at Day 90 in the worse eye. The Schirmer's Test measures the rate of the secretion of tears produced by the eye over 5 minutes. The results indicate the presence of dry eye (Normal = greater than or equal to 15 millimeters (mm) of tears, Dry Eye = less than 15 mm of tears). The smaller the number, the more severe the dry eye.

    Time frame: Baseline, Day 90

  8. Change From Baseline of the Worse Eye in Corneal Staining With Fluorescein at Day 90

    Change from Baseline in corneal staining of the worse eye at Day 90. Sum of corneal staining over 5 zones; each zone was measured on a modified Oxford Scheme (0 = no staining and 5 = severe staining), for a minimum score of 0 and a maximum score of 25. The higher the grade score, the worse the dry eye condition. A negative change from baseline represents a decrease in corneal staining (improvement).

    Time frame: Baseline, Day 90

  9. Change From Baseline of the Worse Eye in Conjunctival Staining With Lissamine Green at Day 90

    Change from Baseline in conjunctival staining of the worse eye using Lissamine Green staining procedure. Sum of conjunctival staining over 6 zones; each zone was measured on a modified Oxford Scheme (0 = no staining and 5 = severe staining), with a minimum score of 0 and a maximum score of 30. The higher the grade score, the worse dry eye condition. A negative number change from baseline represents a decrease in corneal staining (improvement).

    Time frame: Baseline, Day 90

  10. Change From Baseline of the Worse Eye in Tear Break-Up Time (TBUT) at Day 90

    Change from Baseline in TBUT of the worse eye at Day 90. TBUT is the time required for dry spots to appear on the surface of the eye after blinking. The longer it takes, the more stable the tear film. A short TBUT is a sign of poor tear film. A positive number change from baseline indicates an increase in TBUT (improvement).

    Time frame: Baseline, Day 90

  11. Change From Baseline in Study Product Usage at Day 90

    Change from baseline in the study product usage (average number of uses per day) at Day 90. A negative number change from baseline indicates a reduction in eye drop usage (improvement).

    Time frame: Baseline, Day 90

Other outcomes

  1. Number of Patients Prescribed to Each Dosing Regimen at Day 14 and Day 60

    Number of patients prescribed to each dosing regimen at Day 14 and Day 60. At each visit from Day 14 (the first post-operative visit) to Day 60, patients were prescribed to 1 to 4 dosing regimens based on the investigator's clinical evaluation. Dosing schedule options were: At least every 2 hours while awake, 6 to 8 times per day, 3 to 5 times per day, at 1 to 2 times per day.

    Time frame: Day 14, Day 60

07

Results

Posted Dec 14, 2011

Participant flow

Participant flow — Overall Study
MilestoneCarboxymethylcellulose and Glycerin Based Artificial TearCarboxymethylcellulose Based Artificial Tear
Started114114
Completed111109
Not completed35

Outcome measures

PrimaryPost LASIK Dry Eye Symptoms as Measured by Ocular Surface Disease Index (OSDI©) Score at Day 90

Measured on 12 domains (categories); a 5-point scale for each domain (0 = best, no dry eye symptoms, 4 = worst, constant dry eye symptoms). Sum of the domain scores is normalized (standardized) to a severity scale of 0-100 (0 = no symptoms (best score), 100 = maximum severity (worst score)).

Time frame:
Day 90
Reported as:
Mean · Scores on a Scale
Post LASIK Dry Eye Symptoms as Measured by Ocular Surface Disease Index (OSDI©) Score at Day 90
Scores on a ScaleCarboxymethylcellulose and Glycerin Based Artificial TearCarboxymethylcellulose Based Artificial Tear
Post LASIK Dry Eye Symptoms as Measured by Ocular Surface Disease Index (OSDI©) Score at Day 908.32 ± 11.1256.43 ± 8.036
SecondaryPatient Acceptability- Percentage of Patients Who Rated Artificial Tears (AT) as Acceptable at Day 90

A questionnaire was administered to all patients to evaluate the acceptability of the Artificial Tears (referred to as AT). Percentage of patients responding either "Agree" or "Strongly Agree" at day 90 was tabulated. The potential response categories included "Strongly Agree", "Agree", "Neither Agree Nor Disagree", "Disagree" and "Strongly Disagree".

Time frame:
Day 90
Reported as:
Number · Percentage of Patients
Patient Acceptability- Percentage of Patients Who Rated Artificial Tears (AT) as Acceptable at Day 90
Percentage of PatientsCarboxymethylcellulose and Glycerin Based Artificial TearCarboxymethylcellulose Based Artificial Tear
Liked using these AT (112/110)88.493.6
AT helped eyes feel comfortable (112/110)94.694.5
AT were soothing to eyes (111/110)95.595.4
AT protected eyes from dryness (112/109)88.489.9
AT protected eyes from low humidity (112/110)78.682.7
Vision was normal few min.after AT use(112/110)93.892.7
Few min. after use, AT gave clear vision(111/110)94.694.5
AT helped eyes heal from surgery (112/110)83.986.4
AT helped eyes feel same as pre-LASIK (111/110)85.689.1
It's good to use AT after surgery(111/109)97.396.3
SecondaryPatient Acceptability (Sensory) - Percentage of Patients Who Rated Artificial Tears (AT) as Acceptable at Day 90

A patient acceptability - sensory questionnaire was administered to all patients to evaluate the acceptability of the Artificial Tears (AT). Percentage of patients responding either "Agree" or "Strongly Agree" at day 90 was tabulated. The potential response categories included "Strongly Agree", "Agree", "Neither Agree Nor Disagree", "Disagree" and "Strongly Disagree".

Time frame:
Day 90
Reported as:
Number · Percentage of Patients
Patient Acceptability (Sensory) - Percentage of Patients Who Rated Artificial Tears (AT) as Acceptable at Day 90
Percentage of PatientsCarboxymethylcellulose and Glycerin Based Artificial TearCarboxymethylcellulose Based Artificial Tear
Thickness of AT is just right (112/109)79.587.2
AT did not interfere with vision (112/108)64.382.4
AT did not cause my eyes to get crusty (112/108)66.180.6
AT were easy to use (112/109)99.199.1
AT were convenient to use (112/109)96.491.7
AT were important to a good outcome (111/109)82.080.7
AT were helpful to achieve comfort (112/109)92.093.6
AT were helpful to achieve good vision (112/109)71.476.1
I no longer feel I need to use AT (111/108)43.238.0
SecondaryBest Corrected Visual Acuity (BCVA) Status at Day 90

BCVA status at Day 90 reported as the number of patients whose scores were either "Better", "No Change", or "Worse" than their scores at baseline. The status was tabulated as number of lines read correctly at Day 90 minus the number of lines read correctly at baseline. "Better" equals increase of 2 lines or more; "No Change" equals change between -2 to +2 lines; "Worse" equals decrease of 2 lines or more. BCVA is measured using a special eye chart a nd is reported as the number of lines (5 letters per line) read correctly.

Time frame:
Day 90
Reported as:
Number · Number of Patients
Best Corrected Visual Acuity (BCVA) Status at Day 90
Number of PatientsCarboxymethylcellulose and Glycerin Based Artificial TearCarboxymethylcellulose Based Artificial Tear
Better87
No Change104107
Worse10
SecondaryChange From Baseline of the Worse Eye in Corneal Topography as Measured by Pentacam at Day 90

Change from Baseline in corneal topography of the worse eye as measured using a Pentacam system which calculates a number. Corneal topography is a non-invasive medical imaging technique for mapping the surface of the eye. The Pentacam system measures the pupil and anterior segment (the front part of the eye) which provides a range from 10 (best) to 60 (worst). A negative number change from baseline indicates an improvement.

Time frame:
Baseline, Day 90
Reported as:
Mean · Units on a scale
Change From Baseline of the Worse Eye in Corneal Topography as Measured by Pentacam at Day 90
Units on a scaleCarboxymethylcellulose and Glycerin Based Artificial TearCarboxymethylcellulose Based Artificial Tear
Baseline31.95 ± 11.94132.32 ± 15.347
Change from Baseline at Day 90-2.12 ± 6.321-2.24 ± 6.267
SecondaryChange From Baseline of the Worse Eye in Corneal Topography Measured by Humphrey Atlas at Day 90

Change from Baseline in corneal topography of the worse eye as measured by a Humphrey Atlas system which calculates a number. Corneal topography is anon-invasive medical imaging technique for mapping the surface curvature of the cornea (the outer structure of the eye). The higher the number the more irregular the cornea. A Humphrey Atlas system detects irregular conditions in the cornea with a range from 0 = best to 2.5 = worst. A negative number change from baseline indicates an improvement.

Time frame:
Baseline, Day 90
Reported as:
Mean · Units on a scale
Change From Baseline of the Worse Eye in Corneal Topography Measured by Humphrey Atlas at Day 90
Units on a scaleCarboxymethylcellulose and Glycerin Based Artificial TearCarboxymethylcellulose Based Artificial Tear
Baseline1.32 ± 0.8551.25 ± 0.456
Change from Baseline at Day 90-0.49 ± 0.899-0.26 ± 0.396
SecondaryChange From Baseline of Total Higher Order Aberration (HOA) of the Worse Eye at Day 90

Change from Baseline in total HOA of the worse eye. The total HOA number is measured using a machine that calculates and detects changes in the cornea which could occur post Lasik surgery. A negative number change from baseline indicates an improvement.

Time frame:
Baseline, Day 90
Reported as:
Mean · Microns
Change From Baseline of Total Higher Order Aberration (HOA) of the Worse Eye at Day 90
MicronsCarboxymethylcellulose and Glycerin Based Artificial TearCarboxymethylcellulose Based Artificial Tear
Baseline0.521 ± 0.18420.520 ± 0.1845
Change from Baseline at Day 90-0.058 ± 0.1509-0.047 ± 0.1452
SecondaryChange From Baseline of the Worse Eye in Schirmer's Test at Day 90

Change from baseline in Schirmer's Test results at Day 90 in the worse eye. The Schirmer's Test measures the rate of the secretion of tears produced by the eye over 5 minutes. The results indicate the presence of dry eye (Normal = greater than or equal to 15 millimeters (mm) of tears, Dry Eye = less than 15 mm of tears). The smaller the number, the more severe the dry eye.

Time frame:
Baseline, Day 90
Reported as:
Mean · Millimeters of Tears
Change From Baseline of the Worse Eye in Schirmer's Test at Day 90
Millimeters of TearsCarboxymethylcellulose and Glycerin Based Artificial TearCarboxymethylcellulose Based Artificial Tear
Baseline16.3 ± 8.4013.5 ± 6.30
Change from Baseline at Day 90-0.3 ± 8.751.7 ± 9.59
SecondaryChange From Baseline of the Worse Eye in Corneal Staining With Fluorescein at Day 90

Change from Baseline in corneal staining of the worse eye at Day 90. Sum of corneal staining over 5 zones; each zone was measured on a modified Oxford Scheme (0 = no staining and 5 = severe staining), for a minimum score of 0 and a maximum score of 25. The higher the grade score, the worse the dry eye condition. A negative change from baseline represents a decrease in corneal staining (improvement).

Time frame:
Baseline, Day 90
Reported as:
Mean · Scores on a Scale
Change From Baseline of the Worse Eye in Corneal Staining With Fluorescein at Day 90
Scores on a ScaleCarboxymethylcellulose and Glycerin Based Artificial TearCarboxymethylcellulose Based Artificial Tear
Baseline0.5 ± 1.130.5 ± 1.12
Change from Baseline at Day 900.0 ± 1.120.0 ± 1.47
SecondaryChange From Baseline of the Worse Eye in Conjunctival Staining With Lissamine Green at Day 90

Change from Baseline in conjunctival staining of the worse eye using Lissamine Green staining procedure. Sum of conjunctival staining over 6 zones; each zone was measured on a modified Oxford Scheme (0 = no staining and 5 = severe staining), with a minimum score of 0 and a maximum score of 30. The higher the grade score, the worse dry eye condition. A negative number change from baseline represents a decrease in corneal staining (improvement).

Time frame:
Baseline, Day 90
Reported as:
Mean · Scores on a Scale
Change From Baseline of the Worse Eye in Conjunctival Staining With Lissamine Green at Day 90
Scores on a ScaleCarboxymethylcellulose and Glycerin Based Artificial TearCarboxymethylcellulose Based Artificial Tear
Baseline1.0 ± 1.980.8 ± 1.32
Change from Baseline at Day 900.0 ± 1.65-0.3 ± 1.24
SecondaryChange From Baseline of the Worse Eye in Tear Break-Up Time (TBUT) at Day 90

Change from Baseline in TBUT of the worse eye at Day 90. TBUT is the time required for dry spots to appear on the surface of the eye after blinking. The longer it takes, the more stable the tear film. A short TBUT is a sign of poor tear film. A positive number change from baseline indicates an increase in TBUT (improvement).

Time frame:
Baseline, Day 90
Reported as:
Mean · Number of seconds
Change From Baseline of the Worse Eye in Tear Break-Up Time (TBUT) at Day 90
Number of secondsCarboxymethylcellulose and Glycerin Based Artificial TearCarboxymethylcellulose Based Artificial Tear
Baseline13.66 ± 6.13313.25 ± 5.250
Change from Baseline at Day 90-0.92 ± 6.013-0.87 ± 12.924
Other pre-specifiedNumber of Patients Prescribed to Each Dosing Regimen at Day 14 and Day 60

Number of patients prescribed to each dosing regimen at Day 14 and Day 60. At each visit from Day 14 (the first post-operative visit) to Day 60, patients were prescribed to 1 to 4 dosing regimens based on the investigator's clinical evaluation. Dosing schedule options were: At least every 2 hours while awake, 6 to 8 times per day, 3 to 5 times per day, at 1 to 2 times per day.

Time frame:
Day 14, Day 60
Reported as:
Number · Number of patients
Number of Patients Prescribed to Each Dosing Regimen at Day 14 and Day 60
Number of patientsCarboxymethylcellulose and Glycerin Based Artificial TearCarboxymethylcellulose Based Artificial Tear
Day 14: at least every 2 hrs (113/110)2022
Day 14: 6-8 times a day (113/110)3030
Day 14: 3-5 times a day (113/110)5854
Day 14: 1-2 times a day (113/110)54
Day 60: at least every 2 hrs (109/107)43
Day 60: 6-8 times a day (109/107)1214
Day 60: 3-5 times a day (109/107)6260
Day 60: 1-2 times a day (109/107)3130
SecondaryChange From Baseline in Study Product Usage at Day 90

Change from baseline in the study product usage (average number of uses per day) at Day 90. A negative number change from baseline indicates a reduction in eye drop usage (improvement).

Time frame:
Baseline, Day 90
Reported as:
Mean · Number of study product uses per day
Change From Baseline in Study Product Usage at Day 90
Number of study product uses per dayCarboxymethylcellulose and Glycerin Based Artificial TearCarboxymethylcellulose Based Artificial Tear
Baseline (108/108)7.9 ± 3.167.9 ± 4.89
Change from Baseline at Day 90 (108/105)-4.9 ± 3.38-4.5 ± 5.97

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Carboxymethylcellulose and Glycerin Based Artificial Tear—0/114 (0%)88/114 (77.2%)
Carboxymethylcellulose Based Artificial Tear—0/114 (0%)82/114 (71.9%)
Most frequent other events
Most frequent other events
EventCarboxymethylcellulose and Glycerin Based Artificial TearCarboxymethylcellulose Based Artificial Tear
Punctate KeratitisEye disorders21/11422/114
Halo VisionEye disorders10/1149/114
Dry EyeEye disorders10/1148/114
GlareEye disorders8/1147/114
Conjucntival HaemorrhageEye disorders8/1146/114
NasopharyngitisInfections and infestations8/1146/114
Eye Operation ComplicationsInjury, poisoning and procedural complications7/1145/114
PhotophobiaEye disorders5/1147/114
Foreign Body Sensation in EyesEye disorders6/1146/114
Ocular discomfortEye disorders5/1146/114

Baseline characteristics

Age, Customized
Age, Customized(participants)Carboxymethylcellulose and Glycerin Based Artificial TearCarboxymethylcellulose Based Artificial TearTotal
<40 Years8892180
>= 40 Years262248
Sex: Female, Male
Sex: Female, Male(Participants)Carboxymethylcellulose and Glycerin Based Artificial TearCarboxymethylcellulose Based Artificial TearTotal
Female6251113
Male5263115
08

Study locations

1 site
  • San Diego, California, United States
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Sep 2007, a primary completion of Jun 2008 and a completion of Jun 2008. It does not say whether these dates are actual or estimated.

Results were first posted in Dec 2011, 3 years 6 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 12, 2007
First posted
Oct 16, 2007
Start
Sep 2007
Primary completionActual
Jun 2008
CompletionActual
Jun 2008
Results first posted
Dec 14, 2011
Last update
Dec 14, 2011
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 14, 2011, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00544713
Lead sponsor
Allergan
Responsible party
Sponsor
First posted
Oct 16, 2007
Start date
Sep 2007
Primary completion
Jun 2008
Completion
Jun 2008
Results posted
Dec 14, 2011
Last update
Dec 14, 2011

Study contacts

Medical Director
study director · Allergan

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2011. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion